Endometrial cancer (EC) is the most common gynecologic cancer in developed nations with reported 420,368 new cases worldwide in 2022 and resulting in 97,723 deaths that year; it is also one of the few cancers with expected increases in incidence and mortality, which are expected to increase by 50% and 70%, respectively, by 2045. The mortality from EC can largely be attributed to the advanced stage and recurrent cases. Over the past decade, the standard of care for treatment of primary advanced stage and recurrent EC has been chemotherapy, resulting in a median overall survival (OS) of less than 3 years. Advances in molecular tumor profiling have highlighted that a portion of EC tumors release high levels of neoantigens, indicating an opportunity to harness the immune system in therapeutic strategies. On August 1, 2024, the United States Food and Drug Administration expanded the indication of the immunologic anti-PD-1 checkpoint inhibitor, dostarlimab, and chemotherapy in endometrial cancer. This review summarizes the rationale, evidence, and indications for the use of dostarlimab in advanced and recurrent endometrial cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776397 | PMC |
| http://dx.doi.org/10.2147/CMAR.S341469 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiotherapy improves stress urinary incontinence but impairs pelvic floor function in endometrial cancer patients: a prospective cohort study.
Arch Gynecol Obstet
January 2025
Department of Gynecologic Oncology, İzmir Democracy University School of Medicine, Buca Seyfi Demirsoy Education and Research Hospital, İzmir, Turkey.
Purpose: Investigating the impact of radiotherapy on urinary incontinence and pelvic floor dysfunction in endometrial cancer patients.
Method: A comparative study was conducted between endometrial cancer patients who underwent radiotherapy and those who did not receive adjuvant therapy. Patients were assessed during their first follow-up visit at third month post-radiotherapy or post-surgery.
Emerging therapeutic strategies in Lynch syndrome-associated colorectal cancer and the role of MMR testing.
Tumori
January 2025
3rd Surgical Unit, Department of Surgical, Gastroenterological and Oncological Sciences, University of Padua, Padua, Italy.
Lynch syndrome is the most common hereditary cancer predisposition, accounting for 1-5% of colorectal cancer cases, and is driven by germline mutations in DNA mismatch repair genes. Despite established diagnostic criteria, such as the Amsterdam guidelines, Lynch syndrome remains largely underdiagnosed. To address this gap, universal tumour screening has been introduced for all newly diagnosed cases of colorectal cancer and endometrial cancer, significantly improving early detection.
View Article and Find Full Text PDFDifferent surgical methods of hysterectomy for the management of endometrial cancer: a systematic review and network meta-analysis.
Front Oncol
January 2025
Department of Gynecologic Oncology, Chongqing Health Center for Women and Children, Chongqing, China.
Background: Emerging surgical methods are utilized to treat endometrial cancer. The study aimed to assess the efficacy and safety of four common surgical methods of hysterectomy.
Methods: We systematically searched the PubMed, Cochrane Library databases, Medline, EMBASE and Web of Science from their inception until April 30, 2024.
MRI-based intratumoral and peritumoral radiomics for assessing deep myometrial invasion in patients with early-stage endometrioid adenocarcinoma.
Front Oncol
January 2025
Department of MRI, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.
Purpose: To evaluate the effectiveness of magnetic resonance imaging (MRI)-based intratumoral and peritumoral radiomics models for predicting deep myometrial invasion (DMI) of early-stage endometrioid adenocarcinoma (EAC).
Methods: The data of 459 EAC patients from three centers were retrospectively collected. Radiomics features were extracted separately from the intratumoral and peritumoral regions expanded by 0 mm, 5 mm, and 10 mm on unimodal and multimodal MRI.
Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives.
Cancer Manag Res
January 2025
Department of Gynecologic Oncology, University of California, Irvine-Medical Center, Orange, California, USA.
Endometrial cancer (EC) is the most common gynecologic cancer in developed nations with reported 420,368 new cases worldwide in 2022 and resulting in 97,723 deaths that year; it is also one of the few cancers with expected increases in incidence and mortality, which are expected to increase by 50% and 70%, respectively, by 2045. The mortality from EC can largely be attributed to the advanced stage and recurrent cases. Over the past decade, the standard of care for treatment of primary advanced stage and recurrent EC has been chemotherapy, resulting in a median overall survival (OS) of less than 3 years.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!